Transfusion medicine

New York Blood Center Enterprises Makes Investment to Advance Next-Generation Red Blood Cell Research

Retrieved on: 
Jeudi, décembre 7, 2023
SCD, Sickle cell disease, Research development, Research, Health, Doctor of Philosophy, Education, Genetic disorder, Transfusion medicine, Public, Patient, Intelligence, Organization, Nursing

BOSTON, Dec. 07, 2023 (GLOBE NEWSWIRE) -- New York Blood Center Enterprises ( NYBCe ) announced today that its venture fund, NYBC Ventures , has invested in Functional Fluidics to advance research in sickle cell disease and transfusion medicine.

Key Points: 
  • BOSTON, Dec. 07, 2023 (GLOBE NEWSWIRE) -- New York Blood Center Enterprises ( NYBCe ) announced today that its venture fund, NYBC Ventures , has invested in Functional Fluidics to advance research in sickle cell disease and transfusion medicine.
  • Functional Fluidics , a CLIA-certified diagnostics laboratory specializing in red blood cell health, will use the funds to expand its services to Africa and develop the next generation of red blood cell health assays with the potential to improve diagnostic outcomes in sickle cell disease (SCD), transfusion medicine, and other hematological disease areas.
  • SCD is a globally prevalent genetic disorder that affects more than 100,000 Americans and more than 7 million people worldwide.
  • The investment in Functional Fluidics research is the latest effort in the organization’s mission to expand its humanitarian impact on global public health.

QuidelOrtho to Present at 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Vendredi, décembre 22, 2023
Medical Devices, Health, Genetics, Health Technology, Other Health, Biotechnology, Conference, Transfusion medicine

QuidelOrtho Corporation (NASDAQ:QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced that Douglas Bryant, President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024, in San Francisco, CA, scheduled for 12:00 p.m.

Key Points: 
  • QuidelOrtho Corporation (NASDAQ:QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced that Douglas Bryant, President and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024, in San Francisco, CA, scheduled for 12:00 p.m.
  • ET / 9:00 a.m. PT.

QuidelOrtho Receives 510(K) Clearance for Savanna® Multiplex Molecular Platform and Savanna® HSV 1+2/VZV PCR Assay

Retrieved on: 
Mercredi, décembre 20, 2023
Health, FDA, Medical Devices, Infectious Diseases, Hospitals, Genetics, Biotechnology, RNA, Dicarboxylic acid, Food, Virus, Hospital, DNA, PCR, VZV, Laboratory, Transfusion medicine, Infection, Growth, Patient, Diagnosis, QuidelOrtho, Medical device

The clearance allows QuidelOrtho to market and sell the Savanna multiplex molecular platform and the Savanna HSV 1+2/VZV assay to laboratories performing moderate or high complexity diagnostic testing in the United States.

Key Points: 
  • The clearance allows QuidelOrtho to market and sell the Savanna multiplex molecular platform and the Savanna HSV 1+2/VZV assay to laboratories performing moderate or high complexity diagnostic testing in the United States.
  • “Our relentless pursuit of revolutionizing testing across the healthcare continuum has resulted in the achievement of another major milestone – the clearance of our Savanna platform and the Savanna HSV 1+2/VZV assay,” said Douglas Bryant, President and Chief Executive Officer of QuidelOrtho.
  • Savanna is a fully integrated, sample-to-result, automated in vitro diagnostic platform that performs real-time polymerization chain reaction (“PCR”) tests by using the Savanna instrument and Savanna assay cartridges.
  • The Savanna HSV 1+2/VZV test panel is intended to aid in the differential diagnosis of infections with these viruses.

QuidelOrtho to Participate in the Evercore ISI Conference

Retrieved on: 
Jeudi, novembre 16, 2023
Data Management, Health, Technology, Health Technology, General Health, Biotechnology, Evercore, Interest, Transfusion medicine

QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the Evercore ISI conference in Miami, FL, on November 30, 2023.

Key Points: 
  • QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate in the Evercore ISI conference in Miami, FL, on November 30, 2023.
  • Douglas Bryant, President and Chief Executive Officer, will participate in a fireside chat scheduled for 9:10 a.m.
  • ET / 6:10 a.m. PT.
  • Interested parties can access the live webcast and replay, which will be available for 90 days, on the “Events & Presentations” section of the “Investor Relations” page of QuidelOrtho’s website at https://ir.quidelortho.com/ .

EQS-News: EVOMEDIS Announces Strategic Partnership with Medical University of Graz and COREMED Graz to Foster Wound Healing Innovation

Retrieved on: 
Jeudi, décembre 7, 2023
Burns, Medical school, Regenerative medicine, Orphan, Atakent (business cooperation center), Partnership, European Medicines Agency, Transfusion medicine, ATMP, RESEARCH, Serology, Wound healing, GMP, Pharmaceutical industry, Nursing, Austria, Germany

Investing in the future of burn medicine: Alliance to develop new cell-based therapy

Key Points: 
  • Investing in the future of burn medicine: Alliance to develop new cell-based therapy
    Graz, Austria, 23 November 2023 – EVOMEDIS GmbH (EVOMEDIS), an R&D stage life science company developing next-generation wound healing solutions, today announced the initiation of a strategic partnership with the Medical University of Graz (MedUni) and COREMED (Cooperative Center for Regenerative Medicine / JOANNEUM RESEARCH Forschungsgesellschaft mbH) to propel the shift from wound care to wound healing through innovative solutions.
  • EVOMEDIS has pledged an investment of €1.5 million over a span of two years for a collaborative project.
  • We have set up our operations at MedUni, which is part of the Medical Science City Graz (MSCG).
  • This perfectly aligns with our strategy of working closely with local partners to develop new innovations for wound healing up to clinical proof-of-concept.

Cerus Corporation Announces Third Quarter 2023 Financial Results

Retrieved on: 
Jeudi, novembre 2, 2023
Medical Supplies, Health, Hospitals, Health Technology, Other Health, General Health, Biotechnology, CERS, Government, Red blood cell, SG, EBITDA, Research, R, Growth, Corporation, Transfusion medicine, Investment, Patient, Cryptocurrency, Video game, Pharmaceutical industry, Renting, Bookkeeping, Canadian Blood Services, Cerus Corporation

Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2023.
  • Product gross margin for the third quarter of 2023 was 54.9% compared to 55.4% for the third quarter of 2022.
  • R&D expenses for the third quarter of 2023 were $16.8 million, compared to $16.2 million for the third quarter of 2022.
  • Net loss attributable to Cerus Corporation for the third quarter of 2023 was $7.3 million, or $0.04 per basic and diluted share, compared to a net loss attributable to Cerus Corporation of $8.5 million, or $0.05 per basic and diluted share, for the third quarter of 2022.

QuidelOrtho Reports Third Quarter 2023 Financial Results

Retrieved on: 
Mercredi, novembre 1, 2023
Data Management, Medical Supplies, Health, Technology, Health Technology, General Health, Transfusion medicine, Sanfilippo syndrome, EBITDA, QuidelOrtho, EPS, GAAP, COVID-19, Patient, Virus, Pharmaceutical industry

QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced financial results for the third quarter ended October 1, 2023.

Key Points: 
  • QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced financial results for the third quarter ended October 1, 2023.
  • Foreign currency translation did not significantly impact third quarter 2023 results.
  • GAAP diluted loss per share for the third quarter of 2023 was $(0.19), compared to diluted EPS of $0.28 for the third quarter of 2022.
  • The Company is maintaining its 2023 financial guidance, provided on August 8, 2023, as follows:

QuidelOrtho Reports Preliminary Revenue Results for the Third Quarter 2023

Retrieved on: 
Jeudi, octobre 12, 2023
Research, General Health, Pharmaceutical, Data Management, Technology, Infectious Diseases, Clinical Trials, Science, COVID-19, Biotechnology, Other Science, Health, Transfusion medicine, SARS, QuidelOrtho, Pharmaceutical industry

QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced strong preliminary unaudited revenue results for the fiscal third quarter ended October 1, 2023, primarily driven by higher respiratory product sales, particularly SARS and flu.

Key Points: 
  • QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, today announced strong preliminary unaudited revenue results for the fiscal third quarter ended October 1, 2023, primarily driven by higher respiratory product sales, particularly SARS and flu.
  • Total revenues of $738 million to $744 million;
    Non-respiratory product revenue of $557 million to $560 million; and
    Respiratory product revenue of $181 million to $184 million.
  • “Our strong performance in the third quarter reflects the critical role our technologies play in healthcare settings and the trust medical professionals place in us,” said Douglas Bryant, President and Chief Executive Officer, QuidelOrtho.
  • The Company is maintaining its 2023 financial guidance, provided on August 8, 2023, as follows:

Cerus Corporation Announces Workshop and Abstracts at the 2023 AABB Annual Meeting

Retrieved on: 
Mardi, octobre 10, 2023
General Health, Health, Other Health, CDT, American Red Cross, Central Time Zone, Abstract, University of Texas Southwestern Medical Center, UCSF Medical Center, Transfusion medicine, University, Stanford University, Corporation, CERS, Use, Pharmaceutical industry, Vaccine, Cerus Corporation

Cerus Corporation (Nasdaq:CERS) today announced a selection of abstracts and an industry workshop at the 2023 AABB Annual Meeting, taking place in Nashville, TN from October 14 through October 17.

Key Points: 
  • Cerus Corporation (Nasdaq:CERS) today announced a selection of abstracts and an industry workshop at the 2023 AABB Annual Meeting, taking place in Nashville, TN from October 14 through October 17.
  • This year’s AABB Annual Meeting attracts individuals and institutions from around the globe involved in the fields of transfusion medicine and biotherapies.
  • The following is a select list of presentations and abstracts of interest for Cerus.
  • Sunday, October 15, 2023 – 10:00 a.m.– Pathogen Reduced Cryoprecipitate: Early Experiences and Inventory Management Outcomes (Chair: M.S.

QuidelOrtho Receives CLIA Waiver for Sofia® 2 SARS Antigen+ FIA

Retrieved on: 
Jeudi, septembre 21, 2023
FDA, Health, Infectious Diseases, COVID-19, Pharmaceutical, Biotechnology, De novo, FIA, Transfusion medicine, SARS-CoV-2, SARS, QuidelOrtho, Coinfection, CLIA, Risk, WALK, READ, Genetically modified bacteria, Peter Hancock (professor), Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Virus, Food, Disease, Vaccine

QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it has been granted CLIA Waiver from the U.S. Food and Drug Administration (FDA), applying to its new Sofia® 2 SARS Antigen+ FIA.

Key Points: 
  • QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it has been granted CLIA Waiver from the U.S. Food and Drug Administration (FDA), applying to its new Sofia® 2 SARS Antigen+ FIA.
  • The Sofia 2 SARS Antigen+ FIA is the first rapid antigen test that detects COVID-19 to be awarded FDA market clearance through the FDA’s De Novo process and is now the first rapid antigen test also to receive CLIA waiver.
  • With the CLIA waiver, the Sofia 2 SARS Antigen+ FIA is deemed to be so simple and at such low risk of error that it no longer requires administration by trained clinical laboratory personnel, opening broader use in virtually any point-of-care setting equipped with Sofia 2 instruments.
  • “As the first company to introduce a rapid antigen test for COVID-19 when the FDA granted Emergency Use Authorization for the Sofia SARS Antigen FIA in May of 2020, and the first to receive De Novo FDA clearance for our Sofia 2 SARS Antigen+ FIA, it is gratifying to also be the first to receive a full CLIA waiver for our Sofia 2 SARS Antigen+ FIA,” said Douglas Bryant, President and Chief Executive Officer of QuidelOrtho.